KDMN stock forecast
Our latest prediction for Kadmon Holdings, Inc.'s stock price was made on the Sept. 6, 2017 when the stock price was at 2.54$.
In the short term (2weeks), KDMN's stock price should underperform the market by -0.05%. During that period the price should oscillate between -11.54% and +15.51%.
In the medium term (3months), KDMN's stock price should outperform the market by 7.42%. During that period the price should oscillate between -24.23% and +46.68%.Get email alerts
About Kadmon Holdings, Inc.
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.
At the moment the company generates 3M USD in revenues.
On its last earning announcement, the company reported a loss of -0.32$ per share.
The book value per share is 0.86$
Three months stock forecastSept. 6, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|